You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 8, 2024

~ Buy the WYNZORA (betamethasone dipropionate; calcipotriene) Drug Profile, 2024 PDF Report in the Report Store ~

WYNZORA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Wynzora patents expire, and what generic alternatives are available?

Wynzora is a drug marketed by MC2 and is included in one NDA. There are two patents protecting this drug.

This drug has forty-eight patent family members in twenty-eight countries.

The generic ingredient in WYNZORA is betamethasone dipropionate; calcipotriene. There are sixty-six drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.

DrugPatentWatch® Generic Entry Outlook for Wynzora

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for WYNZORA?
  • What are the global sales for WYNZORA?
  • What is Average Wholesale Price for WYNZORA?
Summary for WYNZORA
International Patents:48
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
What excipients (inactive ingredients) are in WYNZORA?WYNZORA excipients list
DailyMed Link:WYNZORA at DailyMed
Drug patent expirations by year for WYNZORA
Pharmacology for WYNZORA

US Patents and Regulatory Information for WYNZORA

WYNZORA is protected by two US patents.

Patents protecting WYNZORA

Topical composition
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mc2 WYNZORA betamethasone dipropionate; calcipotriene CREAM;TOPICAL 213422-001 Jul 20, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Mc2 WYNZORA betamethasone dipropionate; calcipotriene CREAM;TOPICAL 213422-001 Jul 20, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for WYNZORA

See the table below for patents covering WYNZORA around the world.

Country Patent Number Title Estimated Expiration
Poland 3768241 ⤷  Sign Up
Portugal 3768241 ⤷  Sign Up
European Patent Office 3925600 COMPOSITION TOPIQUE COMPRENANT DU CALCIPOTRIOL ET DU DIPROPIONATE DE BETAMETHASONE (TOPICAL COMPOSITION COMPRISING CALCIPOTRIOL AND BETAMETHASONE DIPROPIONATE) ⤷  Sign Up
Japan 2023126762 局所用組成物 (TOPICAL COMPOSITION) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.